About
NINA Medical pioneers a non-invasive treatment for Benign Prostatic Hyperplasia (BPH), a common, non-cancerous enlargement of the prostate that significantly impacts the quality of life and increases the risk of complications in aging men. NINA Medical is at the forefront of this field, offering the world's first non-invasive ultrasound-based treatment, which ensures unparalleled comfort and precision. Founded by experts in medical physics, the company's core technology enables a truly non-invasive (distinct from minimally invasive) approach to the prostate, facilitating both imaging and treatment of BPH within a urologist's office. This groundbreaking solution promotes early intervention without the need for invasive procedures, ensuring men receive treatment without the discomfort associated with traditional methods. NINA Medical has demonstrated technological readiness through animal trials and a preliminary clinical study involving 20 patients, and is now preparing for its first-in-human clinical trial. The company has consistently received support from the Israel Innovation Authority (2019, 2021, 2024) and is backed by private investors. The First-in-Human clinical study is ongoing in an Israeli hospital.